What kills cancer patients—the disease or the treatment?

In oncology, the injuries are predictable. The tracking isn’t.

Cancer treatment saves lives—but it also causes harm, sometimes severe and sometimes fatal. Yet unlike other high-risk industries, these harms are rarely tracked, clearly disclosed, or consistently measured. This section examines what we know, what we don’t track, and why that gap matters.

WHAT THIS SECTION EXAMINES

• Treatment-related risks and mortality
• Known complications that go unmonitored
• Misclassification of treatment-related deaths
• Gaps in data, tracking, and accountability

TWO SYSTEMS: PREVENTION VS TREATMENT

In occupational safety, every injury is recorded, investigated, and used to prevent future harm. In cancer care, treatment comes first—and harm, if recorded at all, is often misattributed, buried, or ignored. The difference is not technical. It’s structural.

I’m a two-time cancer survivor. I received chemotherapy and radiation and now live with long-term effects that were never clearly explained to me—including increased stroke risk years after treatment. This isn’t rare. It’s systemic.

TREATMENT RISKS

Explore documented complications, toxicity, and outcomes.

→ The Human Cost
→ Side Effects: May Include
→ Brain Injury: Treatment Induced

SYSTEM FAILURES

How treatment harm is undercounted and misclassified.

→ Trials: Are Not Tries
→ Legacy Drugs: Present Harm

LONG-TERM CONSEQUENCES

What happens after treatment ends.

→ Radiation: The Honest Hazard

WHAT WE DON’T TRACK

There is no national system to track treatment harm. Death certificates do not capture treatment-related deaths. Registries track diagnosis and survival—but not injury. The result: harm remains largely invisible.

WHAT KILLS CANCER PATIENTS: THE DISEASE OR THE TREATMENT?

This question requires a deeper look at evidence, outcomes, and system design.

→ Read the full analysis